巻号一覧
32 巻 (1986)
- 6Supplement3 号 p. 112･･･
- 6 号 p. 973-
- 5Supplement2 号 p. 843･･･
- 5 号 p. 721-
- 4Supplement1 号 p. 597･･･
- 4 号 p. 481-
- 3 号 p. 343-
- 2 号 p. 199-
- 1 号 p. 1-
32 巻, 5Supplement2 号
選択された号の論文の5件中1～5を表示しています
- |<
- <
- 1
- >
- >|
-
Pipemidicacidとの二重盲検試験による比較検討馬場 駿吉, 木下 治二, 佐々木 亨, 杉森 久一, 佐々木 幸弘, 栗田 二郎, 河本 和友, 原 晃, 古内 一郎, 馬場 広太郎, ...1986 年 32 巻 5Supplement2 号 p. 843-867
発行日: 1986/10/10
公開日: 2013/05/10
ジャーナル フリーIn order to evaluate the clinical efficacy and safety of Norfloxacin (NFLX) in the treatment of acute suppurative otitis media (ASOM) and acute exacerbation of chronic suppurative otitis media (AECSOM), a double blind trial was carried out comparing NFLX with pipemidic acid (PPA). 800 mg/day of NFLX or 2, 000 mg/day of PPA was administered for seven days and the following results were obtained: 1 Clinical efficacy: (1) The clinical efficacy was able to be evaluated in 153 cases of the NFLX group and 155 cases of the PPA group.(2) When judged by the doctors, the overall clinical efficay rate (cases of excellent and good responses) was 68.0 % in the NFLX group and 53.5 % in the PPA group. The efficacy rate of the NFLX group was superior to the PPA group (p<0.01). In ASOM, the NFLX group (79.7 %) showed a higher rate than the PPA group (67.6 %) · (p<0.1). In AECSOM, the NFLX group (59.6 %) was superior to the PPA group (41.7 %) · (p<0.05).(3) When judged by a committee, the overall clinical efficacy rate was 71.2 % in the NFLX group and 51.0 % in the PPA group. The efficacy rate of the NFLX group was superior to the PPA group (p<0.001). In ASOM, no significant difference was found between the NFLX (79.7 %) and PPA group (69.6 %). In AECSOM, the NFLX group (65.2 %) was significantly superior to the PPA group (35.7 %) · (p<0.001). 2 Bacteriological efficacy: (1) As for bacteriological response, the elimination rate was 62.8 % in the NFLX group and 52.8 % in the PPA group. The NFLX group showed the higher rate than the PPA group (p<0.1).(2) In the rate of eradication of S. aureus and P. aeruginosa, the NFLX group showed a higher rate than the PPA group (p<0.1). 3 Safety: (1) Side effects were observed in 7 (4.1 %) of 169 cases in NFLX group and 12 (7.0 %) of 171 cases in PPA group. There was no significant difference between the two groups. From these results, NFLX is judged as a superior drug in the treatment of Suppurative Otitis Media.抄録全体を表示PDF形式でダウンロード (2591K) -
馬場 駿吉, 島田 純一郎, 丸尾 猛, 伊藤 晴夫, 和田 健二, 稲垣 光昭, 本堂 潤, 波多野 努, 征矢野 薫, 加藤 眞二, 高 ...1986 年 32 巻 5Supplement2 号 p. 868-923
発行日: 1986/10/10
公開日: 2013/05/10
ジャーナル フリーIn order to evaluate the clinical efficacy and safety of 3 % Fosfomycin (FOM) otic solution on suppurative otitis media, a double blind study was carried out comparing topical administration of FOM otic solution or placebo solution to patients with chronic suppurative otitis media and its acute exacerbations. Cephalexin was orally administered as a basic treatment. Clinical efficacy was analyzed in 247 patients (126 administered FOM, 121 administered placebo). Side effects were analyzed in 259 patients (129 administered FOM, 130 administered placebo) and clinical usefulness was analyzed in 248 patients (126 administered FOM, 122 administered placebo). The following results were obtained: 1) The overall clinical effectiveness rate judged by chief physicians was 66.7 % for the FOM group and 43.8 % for the placebo group. These results are significantly different. 2) The overall clinical offectiveness rate judged by a committee was significantly different for the two treatments (64.3 % for the FOM group and 40.5 % for the placebo group). 3) As to improvement rate of subjective and objective symptoms, a significant higher rate was obtained with the FOM group than with the placebo group. 4) The bacteriological elimination rate of causative organisms in all cases was 69.2 % treated with FOM and 46.7 % treated with placebo; the difference was significant. 5) Some side effects and adverse reactions were observed in 2 patients (1.6 %) in FOM group and in 2 patients (1.5 %) in the placebo group. Therefore, no singificant difference was observed in the incidence of adverse reactions. All adverse reactions observed were transient and not severe. 6) The overall clinical usefulness rate judged by the chief physicians was significantly greater for the FOM group (67.5 %) than for the placebo group (44.3 %). From the above results it was concluded that 3 % FOM otic solution possessed an excellent antibacterial activity, and is a efficient and safe topical preparation for the treatment of suppurative otitis media.抄録全体を表示PDF形式でダウンロード (4441K) -
馬場 駿吉, 木下 治二, 河村 正三, 藤巻 豊, 和田 昌士, 板橋 隆嗣, 三宅 浩郷, 新川 敦, 坂井 真, 安藤 真姿子, 斎藤 ...1986 年 32 巻 5Supplement2 号 p. 924-945
発行日: 1986/10/10
公開日: 2013/05/10
ジャーナル フリーNorfloxacin (NFLX) 600 mg/day t. i. d., was administered orally to 104 patients of acute paranasal sinusitis (APS) and acute exacerbation of chronic paranasal sinusitis (AECPS). The following results were obtained: (1) The clinical efficacy was evaluated in 51 cases of APS and 47 cases of AECPS.(2) The overall efficacy rate (cases of excellent and good responses) as judged by the attending physician) was 78.6 % of all patients. The efficacy rate was 84.3 % in APS and 72.3 % in AECPS.(3) The overall efficacy rate was 79.6 % as judged by a committee. The efficacy rate were 88.2 % in APS and 70.2 % in AECPS.(4) Bacteriological efficacy rate was 81.5 % (eliminated and replaced). The efficacy rate was 88.9 % in APS and 80.6 % in AECPS.(5) Improvement rates in X-ray fidings were evaluated in 68 cases. The rate of excellent plus good results was 55.9 %, and that of excellent, good plus moderate results was 80.9 %. These two rates were respectively 61.3 % and 83.9 % in APS, and 51.4 % and 78.4 % in AECPS.(6) Side effect was observed in 1 (1 %) of 100 cases. No abnormal laboratory findings were found. From these results, NFLX is judged as a useful drug in the treatment of the paranasal sinusitis.抄録全体を表示PDF形式でダウンロード (5793K) -
難治性, 遷延性症例に対する検討馬場 駿吉, 島田 純一郎, 丸尾 猛, 伊藤 晴夫, 河村 正三, 石井 哲夫, 高山 幹子, 原田 康夫, 田頭 宣治, 築家 大介, ...1986 年 32 巻 5Supplement2 号 p. 946-965
発行日: 1986/10/10
公開日: 2013/05/10
ジャーナル フリーA clinical evaluation of 3 % Fosfomycin ototopical solution was performed in patients with vicious and protracted suppurative otitis media. It is concluded that 3 or 4 daily administrations of 3 % FOM otic solution results in excellent antibacterial activity and is very useful for the treatment of vicious and protracted suppurative otitis media.抄録全体を表示PDF形式でダウンロード (1644K) -
新川 敦, 宮永 守, 武田 啓介, 萩野 仁志, 古屋 栄基, 三宅 浩郷1986 年 32 巻 5Supplement2 号 p. 966-972
発行日: 1986/10/10
公開日: 2013/05/10
ジャーナル フリーWe measured the concentration of AM-715, a member of the pyridone carboxylic acid derivatives, in serum, tissue and secretion in 6 patients with chronic sinusitis and 5 patients with chronic otitis media. When administering 200 mg of the drug, the serum concentration was between 0.40 and 0.77μg/ ml, with an average concentration of 0.55μg/ml (n=9) after 2 hours. The average tissue concentrations reached 1.23μgg/g in maxillary sinus mucosa (n=5) and 2.36μg/g in middle ear mucosa (n=6). The average concentrations were 0.99μg/ml in maxillary sinal fluids (n=3) and 4.46μg/ml in otorrhea (n=3). The drug concentrations in the fluids thus reflect the drug concentrations in the respective tissues.抄録全体を表示PDF形式でダウンロード (755K)
- |<
- <
- 1
- >
- >|